In the autumn of 2005, investigators in New York and New Jersey began pulling apart a scheme that sounds more like a plot from American Horror Story than a case from a modern courtroom. A company called Biomedical Tissue Services, run by former oral surgeon Michael Mastromarino, had been quietly harvesting bone, skin, tendons, and …
AlloClae™™ is marketed as a source of ready-to-use, donor-derived volume. It is not a conventional filler or living fat transplant, and no one has directly studied whether GLP-1 therapy changes what happens after injection. In Part 1 of this series, we ended with an obvious question: if someone continues taking a GLP-1 medication after losing …
Continue reading “THE GLP-1 FILES, PART 2: Will the Fat Even Stay?”
There is a strange paradox taking shape in aesthetic medicine, predicated in large part by GLP-1 therapies for weight loss. No longer a niche treatment, a Gallup survey conducted in May and June 2026, reported that 11% of US adults are currently taking a GLP-1 medication for weight loss, up from 3% in 2024 [1]. …
Continue reading “THE GLP-1 FILES, PART 1: Digging Holes to Fill Them?”
Many guideline failures are not failures of evidence alone, they are failures of process. Economic constraints, logistical complexity, and political realities exert a profound influence on guideline development, yet these forces are rarely discussed in the methodology literature despite being obvious to anyone who has lived through a guideline development process. The previous posts …
In 2025, a systematic review assessed the methodological rigour of 76 clinical practice guidelines published by the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association (ACC/AHA) between 2013 and 2024. These are not obscure documents from minor societies. They are among the most cited, most influential guidelines in medicine, …